148 related articles for article (PubMed ID: 34383409)
1. Functional Annotation of Hypothetical Proteins related to Antibiotic Resistance in Pseudomonas Aeruginosa PA01.
Reem A; Zhong ZH; Al-Shehari WA; Al-Shaebi F; Amran GA; Moeed YAG; Sami R; Khojah E; Askary AE
Clin Lab; 2021 Aug; 67(8):. PubMed ID: 34383409
[TBL] [Abstract][Full Text] [Related]
2. Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients.
Martin LW; Robson CL; Watts AM; Gray AR; Wainwright CE; Bell SC; Ramsay KA; Kidd TJ; Reid DW; Brockway B; Lamont IL
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201819
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
4. Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.
Clark ST; Sinha U; Zhang Y; Wang PW; Donaldson SL; Coburn B; Waters VJ; Yau YCW; Tullis DE; Guttman DS; Hwang DM
Int J Antimicrob Agents; 2019 May; 53(5):620-628. PubMed ID: 30664925
[TBL] [Abstract][Full Text] [Related]
5. Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients.
Colque CA; Albarracín Orio AG; Feliziani S; Marvig RL; Tobares AR; Johansen HK; Molin S; Smania AM
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071060
[No Abstract] [Full Text] [Related]
6. TpiA is a Key Metabolic Enzyme That Affects Virulence and Resistance to Aminoglycoside Antibiotics through CrcZ in Pseudomonas aeruginosa.
Xia Y; Wang D; Pan X; Xia B; Weng Y; Long Y; Ren H; Zhou J; Jin Y; Bai F; Cheng Z; Jin S; Wu W
mBio; 2020 Jan; 11(1):. PubMed ID: 31911486
[TBL] [Abstract][Full Text] [Related]
7. Down-regulatory effects of green coffee extract on las I and las R virulence-associated genes in Pseudomonas aeruginosa.
Jamalifar H; Samadi N; Nowroozi J; Dezfulian M; Fazeli MR
Daru; 2019 Jun; 27(1):35-42. PubMed ID: 31187452
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies.
Pang Z; Raudonis R; Glick BR; Lin TJ; Cheng Z
Biotechnol Adv; 2019; 37(1):177-192. PubMed ID: 30500353
[TBL] [Abstract][Full Text] [Related]
9. Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis.
Lee AC; Jones AL
Paediatr Respir Rev; 2018 Jun; 27():18-20. PubMed ID: 29914746
[TBL] [Abstract][Full Text] [Related]
10. Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis.
Stefani S; Campana S; Cariani L; Carnovale V; Colombo C; Lleo MM; Iula VD; Minicucci L; Morelli P; Pizzamiglio G; Taccetti G
Int J Med Microbiol; 2017 Sep; 307(6):353-362. PubMed ID: 28754426
[TBL] [Abstract][Full Text] [Related]
11. The Pseudomonas aeruginosa genome: how do we use it to develop strategies for the treatment of patients with cystic fibrosis and Pseudomonas infections?
Erwin AL; VanDevanter DR
Curr Opin Pulm Med; 2002 Nov; 8(6):547-51. PubMed ID: 12394165
[TBL] [Abstract][Full Text] [Related]
12. Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis.
Bauernfeind A; Emminger G; Hörl G; Ott S; Przyklenk B; Weisslein-Pfister C
Infection; 1987; 15(5):403-6. PubMed ID: 3121519
[TBL] [Abstract][Full Text] [Related]
13. The periplasmic protein TolB as a potential drug target in Pseudomonas aeruginosa.
Lo Sciuto A; Fernández-Piñar R; Bertuccini L; Iosi F; Superti F; Imperi F
PLoS One; 2014; 9(8):e103784. PubMed ID: 25093328
[TBL] [Abstract][Full Text] [Related]
14. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
Bradbury R; Champion A; Reid DW
Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
[TBL] [Abstract][Full Text] [Related]
15. Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres.
Smith DJ; Ramsay KA; Yerkovich ST; Reid DW; Wainwright CE; Grimwood K; Bell SC; Kidd TJ
Respirology; 2016 Feb; 21(2):329-37. PubMed ID: 26711802
[TBL] [Abstract][Full Text] [Related]
16. Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis.
Sherrard LJ; Tai AS; Wee BA; Ramsay KA; Kidd TJ; Ben Zakour NL; Whiley DM; Beatson SA; Bell SC
PLoS One; 2017; 12(3):e0172179. PubMed ID: 28273168
[TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa: an antibiotic resilient pathogen with environmental origin.
Laborda P; Sanz-García F; Hernando-Amado S; Martínez JL
Curr Opin Microbiol; 2021 Dec; 64():125-132. PubMed ID: 34710741
[TBL] [Abstract][Full Text] [Related]
18. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
Banerjee D; Stableforth D
Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
[TBL] [Abstract][Full Text] [Related]
19. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Smith S; Waters V; Jahnke N; Ratjen F
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
[TBL] [Abstract][Full Text] [Related]
20. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
